GoAI
Get started
EUDA Health Holdings Limited logo

EUDA Health Holdings Limited

EUDA

NASDAQHealthcareMedical - Care Facilities

Open in GoAI

Previous close

$13.21

−$0.99 · -6.97%

Aug 21, 4:00 PM ET

EUDA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

82

Deep Value

Momentum

19

Strong Down

Sentiment

51

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

EUDA Health Limited, established in 2019, is a Singapore-based enterprise dedicated to advancing digital healthcare. It provides an innovative platform facilitating online medical consultations for routine, non-urgent health concerns. This entity functions as a subsidiary of Watermark Developments Limited.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
SG
CEO
Alfred Lim
Listed since
Dec 14, 2021
Employees
123

Market position

Day range

Current $13.21

52-week range

Current $13.21

Open
$13.15
Previous close
$14.20
Volume
1.54K
0.13× average
Average volume
12.3K
Average daily volume
Market cap
24.67M USD
Beta
0.64
Market reference 1
50-day average
$14.7701
-10.56% below average
200-day average
$24.4332
-45.93% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
87.89M USD
P/E (TTM)
-5.16×
P/B (TTM)
-5.77×
P/S (TTM)
2.1×
EV / EBITDA
-42.04×
Earnings yield
-3.23%
Free cash flow yield
-2.95%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
41.73%
Operating margin
-36.42%
Net margin
-40.49%
Return on equity
65.17%
Return on assets
-161.53%
Return on invested capital
136.72%

Financial health

Debt / equity
-0.56×
Current ratio
0.18×
Altman Z-score
-45.21
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends114%-168%-450%-732%Gross margin, FY2021: 27.42%Gross margin, FY2022: 23.11%Gross margin, FY2023: 22.72%Gross margin, FY2024: 19.00%Gross margin, FY2025: 43.88%Operating margin, FY2021: -12.28%Operating margin, FY2022: -151.93%Operating margin, FY2023: -106.87%Operating margin, FY2024: -432.19%Operating margin, FY2025: -35.78%Net margin, FY2021: 18.97%Net margin, FY2022: -661.06%Net margin, FY2023: -270.86%Net margin, FY2024: -382.87%Net margin, FY2025: -40.65%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 27.42%. Gross margin FY2022 23.11%. Gross margin FY2023 22.72%. Gross margin FY2024 19.00%. Gross margin FY2025 43.88%. Operating margin FY2021 -12.28%. Operating margin FY2022 -151.93%. Operating margin FY2023 -106.87%. Operating margin FY2024 -432.19%. Operating margin FY2025 -35.78%. Net margin FY2021 18.97%. Net margin FY2022 -661.06%. Net margin FY2023 -270.86%. Net margin FY2024 -382.87%. Net margin FY2025 -40.65%.

Income trends

Revenue

6.82M USD+70.04%

Operating income

−2.44M USD+85.92%

Net income

−2.77M USD+81.94%
Income trends across reported periods9.99M USD−2.69M USD−15.37M USD−28.05M USDRevenue, FY2021: 4.56M USDRevenue, FY2022: 3.76M USDRevenue, FY2023: 3.71M USDRevenue, FY2024: 4.01M USDRevenue, FY2025: 6.82M USDOperating income, FY2021: −559.99K USDOperating income, FY2022: −5.72M USDOperating income, FY2023: −3.96M USDOperating income, FY2024: −17.34M USDOperating income, FY2025: −2.44M USDNet income, FY2021: 864.83K USDNet income, FY2022: −24.88M USDNet income, FY2023: −10.04M USDNet income, FY2024: −15.36M USDNet income, FY2025: −2.77M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.56M USD. Revenue FY2022 3.76M USD. Revenue FY2023 3.71M USD. Revenue FY2024 4.01M USD. Revenue FY2025 6.82M USD. Operating income FY2021 −559.99K USD. Operating income FY2022 −5.72M USD. Operating income FY2023 −3.96M USD. Operating income FY2024 −17.34M USD. Operating income FY2025 −2.44M USD. Net income FY2021 864.83K USD. Net income FY2022 −24.88M USD. Net income FY2023 −10.04M USD. Net income FY2024 −15.36M USD. Net income FY2025 −2.77M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue6.82M USD4.01M USD3.71M USD3.76M USD4.56M USD
Cost of goods sold3.83M USD3.25M USD2.86M USD2.89M USD3.31M USD
Gross profit2.99M USD762.16K USD842.08K USD870K USD1.25M USD
Research and development249 USD——17.21K USD129.27K USD
Selling, general, and administrative5.43M USD3.34M USD4.8M USD6.75M USD1.81M USD
Operating expenses5.43M USD18.1M USD4.8M USD13.09M USD1.81M USD
Interest income————1.92M USD
Interest expense228.62K USD44.89K USD23.23K USD93.78K USD127.13K USD
Depreciation and amortization406.48K USD173.22K USD111.2K USD256.26K USD264.1K USD
Operating income−2.44M USD−17.34M USD−3.96M USD−5.72M USD−559.99K USD
Net income−2.77M USD−15.36M USD−10.04M USD−24.88M USD864.83K USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
20%
1 beat, 2 misses, 2 met estimates
Average EPS surprise
-551.40%
5 comparable reports
Latest EPS result
0.4
Estimate 0.4 · Met by 0.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.53-0.09-0.71-1.33Q3 '23No estimateQ3 '24MetQ3 '24MissQ3 '25MissQ4 '25BeatQ2 '26MetQ2 '26EstimateQ3 '26Estimate
Q3 2023, reported Jul 31, 2023: actual -0.12, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 28, 2024: actual -0.02, estimate -0.02, surprise 0.00%, Met estimate. Q3 2024, reported Sep 26, 2024: actual -0.282, estimate -0.02, surprise -1310.00%, Miss. Q3 2025, reported Jul 29, 2025: actual -0.324, estimate -0.02, surprise -1520.00%, Miss. Q4 2025, reported Oct 1, 2025: actual -0.324, estimate -1.2, surprise +73.00%, Beat. Q2 2026, reported Apr 28, 2026: actual 0.4, estimate 0.4, surprise 0.00%, Met estimate. Q2 2026, reported May 5, 2026: actual —, estimate -1.2, surprise —, Comparison unavailable. Q3 2026, reported Jul 28, 2026: actual —, estimate 0.4, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates10.29M7.16M4.03M893.76KQ3 '23No estimateQ3 '24BeatQ3 '24MissQ3 '25MissQ4 '25MissQ2 '26MissQ2 '26EstimateQ3 '26Estimate
Q3 2023, reported Jul 31, 2023: actual 1.11M USD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 28, 2024: actual 1.88M USD, estimate 1.34M USD, surprise +40.30%, Beat. Q3 2024, reported Sep 26, 2024: actual 1.05M USD, estimate 2.26M USD, surprise -53.47%, Miss. Q3 2025, reported Jul 29, 2025: actual 1.53M USD, estimate 2.96M USD, surprise -48.36%, Miss. Q4 2025, reported Oct 1, 2025: actual 2.97M USD, estimate 3.9M USD, surprise -23.91%, Miss. Q2 2026, reported Apr 28, 2026: actual 6.17M USD, estimate 6.36M USD, surprise -2.99%, Miss. Q2 2026, reported May 5, 2026: actual —, estimate 3.9M USD, surprise —, Comparison unavailable. Q3 2026, reported Jul 28, 2026: actual —, estimate 9.61M USD, surprise —, Comparison unavailable.

EUDA news

globenewswire.com

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

SINGAPORE, July 30, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a…

Read source
globenewswire.com

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

SINGAPORE, July 30, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a…

Read source
globenewswire.com

EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

SINGAPORE, July 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a…

Read source
globenewswire.com

EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

SINGAPORE, July 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a…

Read source
defenseworld.net

Phreesia (NYSE:PHR) & EUDA Health (NASDAQ:EUDA) Head-To-Head Review

EUDA Health (NASDAQ: EUDA - Get Free Report) and Phreesia (NYSE: PHR - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength…

Read source
globenewswire.com

EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) ("EUDA" or the "Company"), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and…

Read source

Corporate actions

Corporate action history

Stock split

Effective Mar 23, 2026

1:20

EUDA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research EUDA

research.disclaimer